XML 46 R27.htm IDEA: XBRL DOCUMENT
v3.24.3

Shareholders' Equity (Tables) | 6 Months Ended
--- | ---
Sep. 30, 2024
Shareholders' Equity [Abstract] |
Derivative Warrant Liabilities Measured at Fair Value and Reconciliation of Changes in Fair Value | The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:
|  | September 30, 2024 |  |  | September 30, 2023 |
|  |  | $ |  |  |  | $ |
Beginning balance |  |  | 4,359 |  |  |  | — |
Issued during the period |  |  | — |  |  |  | 1,631 |
Change in fair value |  |  | (1,756 | ) |  |  | 1,826 |
Ending balance |  |  | 2,603 |  |  |  | 3,457 |
Fair Value Assumptions | The fair value of derivative warrant liabilities were determined based on the fair value of the Common Warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions that will expire on the earlier of (i) the 60th day after the date of the acceptance by the FDA of an NDA for the Company’s product candidate GTx-104 or (ii) five years from the date on issuance.
|  | September 30, 2024 |  |  | March 31, 2024 |
Risk-free interest rate |  |  | 3.90 | % |  |  | 4.69 | %
Share price |  | $ | 3.00 |  |  | $ | 3.43 |
Expected warrant life |  |  | 1.59 |  |  |  | 2.03 |
Dividend yield |  |  | 0 | % |  |  | 0 | %
Expected volatility |  |  | 69.14 | % |  |  | 85.94 | %

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration